EI
EIKN.O
—
NASDAQ
Biotechnology & Medical Research
Eikon Therapeutics Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-114,8 %
Net margin
—
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$9,88
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Eikon Therapeutics Inc operates in the Healthcare Diagnostics activity within the Biotechnology & Medical Research industry, generating no reported revenue in the latest period while incurring significant operating losses.
Business. Consensus Therapeutics Inc (EIKN.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-114,8 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to EIKN.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Consensus Therapeutics Inc (EIKN.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
AI synthesis
GENERATEDEikon Therapeutics maintains a debt-free capital structure with zero long-term debt and a debt-to-equity ratio of 0.0, supported by a current ratio of 6.34 that indicates strong short-term liquidity coverage. The balance sheet shows total assets of $594.7 million against total liabilities of $312.3 million, resulting in total equity of $282.4 million. Cash and equivalents stand at $104.9 million, which serves as the primary buffer against ongoing cash burn. Operating cash flow is negative at -$188.5 million, and free cash flow is -$361.5 million, driven by capital expenditures of -$46.7 million. The company has 54.1 million basic and diluted shares outstanding, with no immediate dilution flags detected in the risk assessment.
Profitability metrics reflect the pre-revenue stage of the business, with a return on equity of -1.148 and a return on assets of -0.5452. The company reported an operating income of -$338.9 million and a net income of -$324.2 million in the latest period. Without cohort median data for direct comparison, these negative returns are consistent with early-stage biotechnology firms investing heavily in research and development before achieving commercial scale. The absence of revenue means traditional margin analysis is not applicable, and the focus remains on cash preservation and runway extension.
Key takeaways
- Eikon Therapeutics is a pre-revenue biotechnology firm with a debt-free balance sheet and a strong current ratio of 6.34.
- The company is burning cash rapidly, with operating cash flow of -$188.5 million and free cash flow of -$361.5 million in the latest period.
- Profitability metrics are deeply negative, with ROE at -1.148 and ROA at -0.5452, reflecting the investment phase of the business.
- Dilution risk is currently assessed as low, but future capital raises may be necessary to sustain operations given the high cash burn.
- No segment or geographic revenue data is available, and historical trend data is absent, limiting growth trajectory analysis.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$9,20
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$282.4M
Net cashⓘ
$104.9M
Current ratioⓘ
6.3
Debt / equityⓘ
0.0
ROAⓘ
-54.5%
ROEⓘ
-1.1%
Cash conversionⓘ
58.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution6 analysts
Strong buy1
Buy4
Hold0
Sell0
Strong sell1
12-month price target$23,75 · Median $29,00
Low $5,00High $32,00
Operating income · consensus-383,2M USD
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$5,00
Mean$23,75
Median$29,00
High$32,00
Spot$9,20
+158.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-114,8 %Bottom quartile
D/E0,00Above median
Cash Conv0,58Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 18 560 939 sh7 grants11 insiders
- Director, See remarks · Stock Option (Right to Buy) → Common StockAcquired 268 176 @ $14,88grant · 2026-03-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 873 @ $14,88grant · 2026-03-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 873 @ $14,88grant · 2026-03-02
- See Remarks · Stock Option (Right to Buy) → Common StockAcquired 67 044 @ $14,88grant · 2026-03-02
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 87 157 @ $14,88grant · 2026-03-02
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 67 044 @ $14,88grant · 2026-03-02
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 134 088 @ $14,88grant · 2026-03-02
- 10% owner · Series A Preferred Stock → Common StockDisposed 44 249conversion · 2026-02-06
- 10% owner · Series A-1 Preferred Stock → Common StockDisposed 1 403 568conversion · 2026-02-06
- 10% owner · Series C-1 Preferred Stock → Common StockDisposed 110 928conversion · 2026-02-06
- 10% owner · Series A-1 Preferred Stock → Common StockDisposed 47 898conversion · 2026-02-06
- 10% owner · Series D Preferred Stock → Common StockDisposed 688 283conversion · 2026-02-06
- 10% owner · Series C-1 Preferred Stock → Common StockDisposed 3 785conversion · 2026-02-06
- Director, See remarks · Series D Preferred Stock → Common StockDisposed 114 714conversion · 2026-02-06
- Director, See remarks · Series A-1 Preferred Stock → Common StockDisposed 170 143conversion · 2026-02-06
- 10% owner · Series A Preferred Stock → Common StockDisposed 1 296 629conversion · 2026-02-06
- Director, 10% owner · Series C-1 Preferred Stock → Common StockDisposed 194 510conversion · 2026-02-06
- Director, 10% owner · Series D Preferred Stock → Common StockDisposed 1 376 566conversion · 2026-02-06
- 10% owner · Series A Preferred Stock → Common StockDisposed 1 340 878conversion · 2026-02-06
- 10% owner · Series A-1 Preferred Stock → Common StockDisposed 1 046 827conversion · 2026-02-06
- 10% owner · Series A-1 Preferred Stock → Common StockDisposed 335 521conversion · 2026-02-06
- 10% owner · Series B Preferred Stock → Common StockDisposed 106 785conversion · 2026-02-06
- 10% owner · Series B Preferred Stock → Common StockDisposed 71 190conversion · 2026-02-06
- 10% owner · Series B-1 Preferred Stock → Common StockDisposed 709 234conversion · 2026-02-06
- Director, 10% owner · Series A Preferred Stock → Common StockDisposed 1 340 878conversion · 2026-02-06
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Equitynet_income / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
Source documents
- Eikon Therapeutics Inc Market data — financials · 2026-07-28
- reconciler_enqueue (reconciler) on EIKN.O · 2026-07-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$11M
- Institutional Investor · as of 2026-03-310,00 %$41M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Roger M. PerlmutterChairman of the Board, Chief Executive Officer
Insider activity
Net buying7 buys · 0 sellsnet $46,1M6 insiders · last 365d
- 10% owner · Common StockBought 49 556 @ $18,00$892K · 2026-02-06
- Director, See remarks · Common StockOther 284 857 · 2026-02-06
- Director, 10% owner · Common StockOther 2 155 765 · 2026-02-06
- 10% owner · Common StockOther 1 296 629 · 2026-02-06
- 10% owner · Common StockOther 1 403 568 · 2026-02-06
- 10% owner · Common StockOther 110 928 · 2026-02-06
- 10% owner · Common StockOther 44 249 · 2026-02-06
- 10% owner · Common StockOther 47 898 · 2026-02-06
- 10% owner · Common StockOther 2 387 705 · 2026-02-06
- 10% owner · Common StockOther 3 785 · 2026-02-06
- 10% owner · Common StockOther 688 283 · 2026-02-06
- Director, 10% owner · Common StockOther 2 387 705 · 2026-02-06
- 10% owner · Common StockBought 1 437 323 @ $18,00$25,9M · 2026-02-06
- 10% owner · Common StockOther 1 151 540 · 2026-02-06
- Director, 10% owner · Common StockOther 1 151 540 · 2026-02-06
- 10% owner · Common StockBought 630 881 @ $18,00$11,4M · 2026-02-06
- 10% owner · Common StockOther 2 155 765 · 2026-02-06
- 10% owner · Common StockOther 408 725 · 2026-02-04
- 10% owner · Common StockOther 1 340 878 · 2026-02-04
- 10% owner · Common StockOther 335 521 · 2026-02-04
- 10% owner · Common StockOther 37 855 · 2026-02-04
- 10% owner · Common StockOther 229 428 · 2026-02-04
- 10% owner · Common StockOther 697 885 · 2026-02-04
- 10% owner · Common StockOther 1 626 · 2026-02-04
- 10% owner · Common StockOther 67 207 · 2026-02-04
Short positioning
4.6Mshares short-0.1% vs prior
11.47days to cover
74.7%short of daily vol
3.9Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
EIKN.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Shares outstanding (annual): 3.07MUnknown
- Total assets (annual): USD 594.73MUnknown
- Current assets (annual): USD 348.92MUnknown
- Total liabilities (annual): USD 312.3MUnknown
- Current liabilities (annual): USD 55.01MUnknown
- Cash & equivalents (annual): USD 104.9MUnknown
- Shareholders' equity (annual): USD -879.03MUnknown
- Shareholders' equity (annual): USD -571.93MUnknown
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-03-02 00:00 UTCINSIDER7 insider transactions — 2026-03 7 derivative
2026-03-02 00:00 UTCINSIDER7 insider transactions — 2026-03 7 derivative
2026-03-02INSIDERBaynes Roy D. acquired 134.1k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-03-02INSIDERThorner Benjamin Bruno acquired 67.0k sh Stock Option (Right to Buy) — See Remarks
2026-03-02INSIDERPERLMUTTER ROGER M acquired 268.2k sh Stock Option (Right to Buy) — Director, See remarks
2026-03-02INSIDERBowie Alfred Lloyd Jr. acquired 67.0k sh Stock Option (Right to Buy) — Chief Financial Officer
2026-03-02INSIDERHuffines Robert Luther acquired 25.9k sh Stock Option (Right to Buy) — Director
2026-03-02INSIDERKlobuchar Michael A acquired 87.2k sh Stock Option (Right to Buy) — Chief Operating Officer
2026-03-02INSIDERFRAZIER KENNETH C acquired 25.9k sh Stock Option (Right to Buy) — Director
2026-02-06 00:00 UTCINSIDER74 insider transactions — 2026-02 · net buy $46.1M 41 derivative
2026-02-06 00:00 UTCINSIDER74 insider transactions — 2026-02 · net buy $46.1M 41 derivative
2026-02-06INSIDERColumn Group IV GP, LP bought 49.6k sh — 10% owner ~$892k
2026-02-06INSIDERPERLMUTTER ROGER M transacted 284.9k sh — Director, See remarks
2026-02-06INSIDERWolfe Josh transacted 2.16M sh — Director, 10% owner
2026-02-06INSIDERColumn Group IV GP, LP transacted 1.30M sh — 10% owner
2026-02-06INSIDERColumn Group IV GP, LP transacted 1.40M sh — 10% owner
2026-02-06INSIDERColumn Group IV GP, LP transacted 110.9k sh — 10% owner
2026-02-06INSIDERColumn Group IV GP, LP transacted 44.2k sh — 10% owner
2026-02-06INSIDERColumn Group IV GP, LP transacted 47.9k sh — 10% owner
2026-02-06INSIDERLux Venture Partners V, LLC transacted 2.39M sh — 10% owner
2026-02-06INSIDERColumn Group IV GP, LP transacted 3.8k sh — 10% owner
2026-02-06INSIDERColumn Group IV GP, LP transacted 688.3k sh — 10% owner
2026-02-06INSIDERWolfe Josh transacted 2.39M sh — Director, 10% owner
2026-02-06INSIDERColumn Group IV GP, LP bought 1.44M sh — 10% owner ~$25.87M
2026-02-06INSIDERLux Venture Partners V, LLC transacted 1.15M sh — 10% owner
2026-02-06INSIDERWolfe Josh transacted 1.15M sh — Director, 10% owner
2026-02-06INSIDERColumn Group IV GP, LP bought 630.9k sh — 10% owner ~$11.36M
2026-02-06INSIDERLux Venture Partners V, LLC transacted 2.16M sh — 10% owner
2026-02-06INSIDERColumn Group IV GP, LP disposed of 28.2k sh Series C-1 Preferred Stock — 10% owner
2026-02-06INSIDERPERLMUTTER ROGER M disposed of 1.27M sh Series A-1 Preferred Stock — Director, See remarks
2026-02-06INSIDERPERLMUTTER ROGER M disposed of 855.5k sh Series D Preferred Stock — Director, See remarks
2026-02-06INSIDERColumn Group IV GP, LP disposed of 9.67M sh Series A Preferred Stock — 10% owner
Showing the 40 most recent of 54 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage